Growth Metrics

Pacific Biosciences Of California (PACB) Total Non-Current Liabilities (2016 - 2025)

Pacific Biosciences Of California has reported Total Non-Current Liabilities over the past 13 years, most recently at $778.7 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $778.7 million for Q4 2025, up 3.38% from a year ago — trailing twelve months through Dec 2025 was $778.7 million (up 3.38% YoY), and the annual figure for FY2025 was $778.7 million, up 3.38%.
  • Total Non-Current Liabilities for Q4 2025 was $778.7 million at Pacific Biosciences Of California, up from $767.1 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for PACB hit a ceiling of $1.2 billion in Q4 2021 and a floor of -$200.0 million in Q3 2021.
  • Median Total Non-Current Liabilities over the past 5 years was $1.0 billion (2023), compared with a mean of $942.8 million.
  • Biggest five-year swings in Total Non-Current Liabilities: skyrocketed 1459.76% in 2021 and later fell 27.84% in 2024.
  • Pacific Biosciences Of California's Total Non-Current Liabilities stood at $1.2 billion in 2021, then decreased by 0.79% to $1.2 billion in 2022, then fell by 13.21% to $1.0 billion in 2023, then fell by 27.84% to $753.3 million in 2024, then rose by 3.38% to $778.7 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $778.7 million (Q4 2025), $767.1 million (Q3 2025), and $764.0 million (Q2 2025) per Business Quant data.